Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €46.66B | 12x | 0.69 | €432.10 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharmaceuticals | Milan | Healthcare | Biotechnology & Medical Research | €46.11B | 12x | 0.7 | €440 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €46.11B | 12x | 0.7 | €439.80 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €43.25B | 58x | €610.62 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €31.59B | 33.5x | 0.09 | €515.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €31.59B | 33.5x | 0.09 | €516.20 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €31.58B | 33.5x | 0.09 | €512.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €31.58B | 33.5x | 0.09 | €518.40 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €23.15B | 20.6x | 70.2 | €133.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Milan | Healthcare | Biotechnology & Medical Research | €23.15B | 20.6x | 70.12 | €133.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €22.86B | -29.9x | 0.03 | €95.95 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €22.86B | -29.9x | 0.03 | €96.10 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €22.84B | -29.9x | 0.03 | €96 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €11.94B | 12x | 0.04 | €194.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €11.93B | 12x | 0.04 | €187.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | BATS Europe | Healthcare | Biotechnology & Medical Research | €11.22B | 33.3x | 0.73 | €58.38 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Frankfurt | Healthcare | Biotechnology & Medical Research | €11.22B | 33.3x | 0.73 | €57.72 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €11.21B | 33.3x | 0.73 | €57.66 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Paris | Healthcare | Biotechnology & Medical Research | €11.21B | 33.3x | 0.73 | €58.16 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.4% Downside | Upgrade to Pro+ | |
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €10.20B | 18.9x | 0.08 | €38.03 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Xetra | Healthcare | Biotechnology & Medical Research | €9.56B | -3.2x | -0.07 | €24.78 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €9.56B | -3.2x | -0.07 | €24.82 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | €9.52B | -3.2x | -0.07 | €24.84 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €9.52B | -3.2x | -0.07 | €24.74 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €9.17B | -24.6x | -0.74 | €150 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €8.68B | 106.4x | -1.46 | €40.17 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €8.68B | 106.4x | -1.43 | €40.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.68B | 106.4x | -1.43 | €39.97 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | |
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.68B | 106.4x | -1.43 | €40.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.68B | 106.4x | -1.43 | €40.03 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €7.24B | -52.1x | -0.87 | €111.55 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €4.97B | -11.9x | 0.96 | €30.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.58B | -9.8x | 0.27 | €48.20 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.87B | -5.5x | 0.02 | €12.77 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.79B | -4x | 0.02 | €32.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €1.79B | -4x | 0.02 | €32.60 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.79B | -4x | 0.02 | €33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.63B | -9.1x | 0.06 | €25.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | €1.62B | -9.1x | 0.06 | €24.60 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.6% Upside | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.62B | -9.1x | 0.06 | €24.82 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.54B | -330x | 2.94 | €23.52 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.54B | -330x | 2.95 | €23.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.28B | -6.2x | 0.05 | €7.19 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.28B | -6.2x | 0.04 | €6.99 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.28B | -6.2x | 0.05 | €7.23 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.28B | -6.2x | 0.05 | €7.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.28B | -6.2x | 0.05 | €7.20 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GNI | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.20B | -196.7x | 1.82 | €23.40 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.06B | 2.5x | 0.01 | €6.53 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €1.06B | 2.5x | 0.01 | €6.56 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |